Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 6/20 | 0.69 |
| ▸ | SSTR5 | P35346 | 14/20 | 0.58 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15366968 | 0.85 | SMYD3 (0.67) | SMYD3 | |
| SCHEMBL16415945 | 0.83 | ALDH1A1 (0.53) | SMYD3 | |
| SCHEMBL19133764 | 0.82 | HDAC4 (0.47) | SMYD3 | |
| SCHEMBL30419625 | 0.82 | SMYD3 (1.00) | SMYD3SSTR5 | |
| SCHEMBL21489983 | 0.82 | SMYD3 (1.00) | SMYD3SSTR5 | |
| SCHEMBL2964004 | 0.82 | SMYD3 (0.71) | SMYD3SSTR5SSTR1HRH1 | |
| SCHEMBL19701356 | 0.82 | SMYD3 (1.00) | SMYD3SSTR5 | |
| SCHEMBL27704323 | 0.81 | SMYD3 (0.59) | SMYD3SSTR5SSTR1HRH1KCNH2 | |
| SCHEMBL2953693 | 0.80 | SMYD3 (0.58) | SMYD3SSTR5SSTR1HRH1 | |
| SCHEMBL2957930 | 0.80 | SSTR5 (0.72) | SSTR5SSTR1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | Epizyme, Inc. | 2024-09-12 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240299352-A1 | COMBINATION THERAPIES WITH SETD2 INHIBITORS | SETD2, CARM1, SETDB1 | SMYD3 386/4885SSTR5 4085/4885SSTR1 3938/4885 |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | EZH2, HDAC2, SETD2 | SMYD3 489/4885SSTR5 4008/4885SSTR1 4332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.